Filtered By:
Therapy: Neoadjuvant Therapy
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Safety and Efficacy of MEDI0457 Plus Durvalumab in Patients With Human Papillomavirus-associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
CONCLUSIONS: MEDI0457 plus durvalumab was well tolerated. While the primary efficacy endpoint was not reached, clinical benefit was encouraging.PMID:36455147 | DOI:10.1158/1078-0432.CCR-22-1987
Source: Clinical Cancer Research - December 1, 2022 Category: Cancer & Oncology Authors: Charu Aggarwal Nabil F Saba Alain Algazi Ammar Sukari Tanguy Y Seiwert Missak Haigentz Mercedes Porosnicu Marcelo Bonomi Jean Boyer Mark T Esser Lily I Cheng Sonia Agrawal Emily C Jennings Nicholas M Durham Karl Fraser Delphine Lissa Maozhen Gong Natalia Source Type: research
